Home Newsfeeds Johnson & Johnson CFO Says Modifying Covid-19 Vaccine Research Programs And Manufacturing Capacity To Levels That Meet Customer Contractual Commitments; Says

News

Johnson & Johnson CFO Says Modifying Covid-19 Vaccine Research Programs And Manufacturing Capacity To Levels That Meet Customer Contractual Commitments; Says

Co Says Modifying Covid-19 Vaccine Program Will Result In Incremental Costs For The Year Which Will Be Reflected As A Special Item

byBenzinga Newsdesk

July 19, 2022

1 minute read

Co Says Modifying Covid-19 Vaccine Program Will Result In Incremental Costs For The Year Which Will Be Reflected As A Special Item

Keybanc Maintains Overweight on Udemy, Raises Price Target to $16

By Benzinga Newsdesk

August 4, 4:39 AM

Keybanc analyst Jason Celino maintains Udemy (NASDAQ:UDMY) with a Overweight and raises the price target from $15 to $16.

UDMY

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented At 2023 APSARD Conference

By Benzinga Newsdesk

January 19, 9:42 AM

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of

ABVC